Results 31 to 40 of about 50,964 (281)

Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis [PDF]

open access: yes, 2011
Background: Single drug use has not achieved satisfactory results in the treatment of prostate cancer, despite application of increasingly widespread targeted therapeutics.
Eva Juengel   +29 more
core   +1 more source

Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen. [PDF]

open access: yesPLoS ONE, 2012
As prostate cancer progresses to castration-resistant disease, there is an increase in signal transduction activity. Most castration-resistant prostate tumors continue to express the androgen receptor (AR) as well as androgen-responsive genes, despite ...
Hilary Whitworth   +7 more
doaj   +1 more source

Knowledge mapping of immunotherapy in castration-resistant prostate cancer: a bibliometric and visualized study (2003–2022)

open access: yesFrontiers in Urology, 2023
ObjectiveTo utilize bibliometric analysis to examine the literature about immunotherapy for castration-resistant prostate cancer published within the past two decades.
Xianfu Cai   +5 more
doaj   +1 more source

Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 [PDF]

open access: yes, 2023
Background: Innovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant to making management decisions
Yu, EY   +568 more
core   +1 more source

Autocrine activation of MAPK signaling mediates intrinsic tolerance to androgen deprivation in LY6D prostate cancer cells

open access: yesCell Reports, 2023
Summary: The emergence of castration-resistant prostate cancer remains an area of unmet clinical need. We recently identified a subpopulation of normal prostate progenitor cells, characterized by an intrinsic resistance to androgen deprivation and ...
Ivana Steiner   +16 more
doaj   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer. [PDF]

open access: yesMol Oncol
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Gordon N   +13 more
europepmc   +2 more sources

Darolutamide For Castration-Resistant Prostate Cancer.

open access: yesOncoTargets and therapy, 2019
The treatment landscape of advanced prostate cancer continues to evolve rapidly, with newer and more active drugs being used in earlier phases of the disease based on improved overall survival. After adoption of docetaxel for metastatic castration-sensitive disease, large trials with next-generation androgen receptor-signaling inhibitors (abiraterone ...
Bastos,Diogo A, Antonarakis,Emmanuel S
openaire   +3 more sources

Single-Cell Analysis Identifies LY6D as a Marker Linking Castration-Resistant Prostate Luminal Cells to Prostate Progenitors and Cancer

open access: yesCell Reports, 2018
Summary: The exact identity of castrate-resistant (CR) cells and their relation to CR prostate cancer (CRPC) is unresolved. We use single-cell gene profiling to analyze the molecular heterogeneity in basal and luminal compartments.
João D. Barros-Silva   +14 more
doaj   +1 more source

Amplification of KCNMA1 : a potential therapeutic target in prostate cancer [PDF]

open access: yes, 2007
Prostate cancer is the most common cancer in males and the second leading cause of cancer deaths in western countries. Although most prostate cancers initially respond well to androgen withdrawal, they become inevitably resistant to this treatment and ...
Bloch, Michael
core   +1 more source

Castrate‐resistant prostate cancer: the future of antiandrogens [PDF]

open access: yesTrends in Urology & Men's Health, 2014
AbstractSeveral promising new treatment options for men with castrate‐resistant prostate cancer have become available recently. The authors look at developments in this rapidly progressing area.
Pshezhetskiy, Dmitry   +2 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy